Pipeline

Endeavor

to Develop Leading Medicines

Pipeline

We are focused on developing transformative medicines by targeting the underlying genetic and cellular causes of disease with best-in-class agents. At Endeavor, we will continue to build and advance our pipeline as we acquire additional assets that show promise in improving patient lives.

Program

Preclinical

Phase 1

Phase 2

Phase 3

ENV-101

Oncology
Hedgehog Inhibitor
Phase 2

ENV-101

IPF
Hedgehog Inhibitor
Phase 2

ENV-201

Oncology
ULK1/2 Inhibitor
Preclinical

ENV-101

ENV-101 is a small molecule Hedgehog signaling inhibitor that has demonstrated significant clinical efficacy and safety. We are developing ENV-101 as a precision therapy in multiple types of cancer, as well as in idiopathic pulmonary fibrosis (IPF) – where the Hedgehog pathway is implicated as a driver of the disease.

The clinical effects of ENV-101 have been evaluated in nearly 200 people. Six completed studies have characterized the pharmaceutical properties, including PK/PD in patients with advanced solid tumors and demonstrated a superior safety profile compared to similar therapeutics in this class. Across studies enrolling advanced cancer patients, responses were observed at all doses and in multiple tumor types.

ENV-ONC-101

We are developing ENV-101 for patients with tumor mutations in the Hedgehog pathway, which affect approximately 2% of all cancers. Mutations in this pathway can aberrantly activate downstream signaling resulting in proliferation, survival and metastasis of cancer cells. ENV-101 potently and safely inhibits the activity of the Hedgehog pathway which may have a significant benefit on the lives of cancer patients with these mutations.

We are currently enrolling for this trial.

For more information on our trial (NCT05199584): A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations, please visit www.clinicaltrials.gov.

ENV-IPF-101

We are developing ENV-101 for patients with idiopathic pulmonary fibrosis (IPF), that has the potential to revolutionize the current standard of care. IPF is characterized by progressive lung scarring and reduction in lung volume. Pathologically, it is a wound that won’t heal.

We are currently enrolling for this trial.

For more information on our trial (NCT04968574): A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF), please visit www.clinicaltrials.gov.

ENV-201

ENV-Oncology-201

ENV-201 is a small molecule inhibitor of ULK1/2 for tumors dependent on autophagy such as cancers with RAS and/or STK11 mutations. ENV-201 potently inhibits a novel target with extensive monotherapy activity preclinically. We are currently evaluating ENV-201 in IND-enabling studies.

For more information about our clinical trials please contact us at:

Expanded Access

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Egestas sed tempus urna et pharetra pharetra massa massa. Volutpat diam ut venenatis tellus in metus. Ullamcorper malesuada proin libero nunc consequat interdum varius. Fames ac turpis egestas maecenas pharetra convallis posuere. Hendrerit gravida rutrum quisque non. Pellentesque pulvinar pellentesque habitant morbi tristique senectus. Risus pretium quam vulputate dignissim suspendisse.

Quis risus sed vulputate odio ut. Quis eleifend quam adipiscing vitae proin sagittis. Volutpat diam ut venenatis tellus. Arcu dui vivamus arcu felis bibendum ut tristique et egestas. Massa vitae tortor condimentum lacinia quis vel eros donec ac. Tincidunt ornare massa eget egestas purus viverra. Congue eu consequat ac felis donec et odio. Gravida in fermentum et sollicitudin ac. Natoque penatibus et magnis dis parturient montes. Porttitor lacus luctus accumsan tortor posuere ac ut.